Moreover, tumor regression was TAA-specific: ISB 2001 at 0.5 mg kg−1 induced complete regression of established KMS-12-BM, whereas a control molecule targeting only CD3ε (CD3 × DU × DU) had no effect at the same dose (Fig. 7d). Here, CD3E is linked to neoplasm.